Literature DB >> 17362465

Immune recovery uveitis in an HIV-negative individual.

Michelle L Baker, Penelope Allen, Jake Shortt, Sharon R Lewin, Andrew Spencer.   

Abstract

Immune recovery uveitis (IRU) is an intraocular inflammatory disorder originally described in individuals with human immunodeficiency virus (HIV) and inactive cytomegalovirus retinitis following highly active antiretroviral therapy. Although relatively common in individuals with acquired immune deficiency syndrome in the United States it is an extremely uncommon presentation in Australia. IRU also occurs in iatrogenically immunosuppressed individuals with a similar incidence to HIV-infected individuals. We report one case of IRU in an HIV-negative individual following a volunteer unrelated donor allogeneic stem cell transplant for non-Hodgkin's lymphoma. In the context of tapering the immunosuppression the patient developed bilateral IRU, consisting of panuveitis and macular oedema. The visual acuity (VA) at presentation of IRU was limited to counting fingers bilaterally. The IRU resolved with the re-intensification of the immunosuppression. VA restored to right 6/18 and left 6/12.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362465     DOI: 10.1111/j.1442-9071.2006.01439.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  2 in total

1.  Spectral domain optical coherence tomography and fundus autofluorescence findings in cytomegalovirus retinitis in HIV-infected patients.

Authors:  Shigeko Yashiro; Takeshi Nishijima; Yuuka Yamamoto; Yumi Sekine; Natsuyo Yoshida-Hata; Tomohiro Iida; Shinichi Oka
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

2.  A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma.

Authors:  Petra Svozílková; Jarmila Heissigerová; Michaela Brichová; Bohdana Kalvodová; Jan Dvořák; Eva Ríhová
Journal:  Virol J       Date:  2013-01-07       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.